Implant Sciences CEO Invited to Attend Inaugural U.S.-Africa Business Forum by U.S. Department of Commerce
Glenn Bolduc joins President Barack Obama, African leaders, and leading U.S. and African CEOs in an event focused on strengthening commercial and business ties between the U.S. and Africa
WILMINGTON, Mass., Aug. 5, 2014 /PRNewswire/ — Implant Sciences Corporation (OTCQB: IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, today announced its CEO Glenn D. Bolduc has been invited to attend the U.S.-Africa Business Forum on Tuesday, August 5, 2014 in Washington D.C. Mr. Bolduc is one of a select group of U.S. CEOs invited to the event co-hosted by the U.S. Department of Commerce and Bloomberg Philanthropies. Heads of state will engage with business executives from both sides of the Atlantic in conversations about successes and solutions to build greater access for trade and investment in Africa. President Obama will participate in the conversation with CEOs and government leaders from the U.S. and Africa.
The first-ever U.S.-Africa Business Forum will be part of President Obama’s U.S.-Africa Leaders Summit, the first summit of its kind, and the largest event that any U.S. president has ever convened with African heads of state or government.
“I’m honored to be invited to this event on behalf of Implant Sciences. Africa is a key export market for our American-made explosives trace detectors and I look forward to joining the conversation with African executives, heads of state, and President Obama. Through our relationship with the U.S. Department of Commerce, our established sales and distribution network in Africa, and strong record of customer satisfaction, we continue to drive sales in the region. We appreciate the support we’ve received from the U.S. Department of Commerce,” Bolduc stated.
About Implant Sciences
Implant Sciences is a leader in developing and manufacturing advanced detection capabilities to counter and eliminate the ever-evolving threats from explosives and drugs. The Company’s team of dedicated trace detection experts has developed proprietary technologies used in its commercial products, thousands of which have been sold across more than 50 countries worldwide. Implant Sciences is only the third manufacturer, and the sole American-owned company, to currently have an ETD system named as a Qualified Product by the US Transportation Security Administration. The Company’s ETDs have received approvals and certifications from several international regulatory agencies including the TSA in the U.S., STAC in France, the German Ministry of the Interior, and the Ministry of Public Safety in China. It also received a GSN 2013 Homeland Security Award for “Best Explosives Detection Solution”. All Implant Sciences products are recognized as Qualified Anti-Terrorism Technologies by the Department of Homeland Security. For further details on the Company and its products, please visit the Company’s website at www.implantsciences.com.
Safe Harbor Statement
This press release may contain certain “forward-looking statements,” as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management’s current expectations and are subject to risks and uncertainties that could cause the Company’s actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change, and our success will depend on our ability to develop and introduce new products; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including our most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management’s current expectations and assumptions which could differ materially from the forward-looking statements.
Implant Sciences Corporation
Glenn Bolduc, CEO
SOURCE Implant Sciences Corporation